In a post-hoc analysis of a phase 3, open-label, 52-week LTE trial presented at the American Headache Society 68th Annual Scientific Meeting in Orlando, FL., ubrogepant 100 mg showed consistent 2-hour pain...
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, will address migraine-related diagnosis, treatment, red flags, and care considerations across...
In this expert interview, W. Clay Jackson, MD, DipTh, discusses why deprescribing should be approached through shared decision-making, careful medication review, and attention to each patient’s current...
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.
A systematic review and meta-analysis evaluated whether pharmacist-led deprescribing interventions reduce polypharmacy and potentially inappropriate medications among older adults across care settings.
...
A stepped-wedge cluster randomized trial evaluated whether pairing electronic decision support with routine medication reviews increases deprescribing of potentially inappropriate medications among older...
New guideline recommendations from the ACC/AHA and 9 partner organizations prioritize earlier treatment, refined atherosclerotic cardiovascular disease risk prediction, and broader use of lipid biomarkers...
In a prospective cohort of children in California who were prenatally exposed to selective serotonin reuptake inhibitors (SSRIs), investigators examined whether additional exposure to SSRIs via breast milk...
